Glycoengineered Protein-based Glycomedicine Development

CD BioGlyco has accumulated extensive experience in the field of glycomedicine development. We customize systematic solutions according to customers' scientific research needs in glycomedicine development. We have the confidence to be your essential research assistant in the field of glycobiology.

Functions of Glycoengineered Protein

With the deepening of our understanding of biology, recombinant proteins have become an important class of biological macromolecules that are widely used in medicine, industry, agriculture, environmental protection, and other fields. In the arena of medicine, therapeutic proteins, such as antibodies, cytokines/growth factors, and hormones, are indispensable for the prevention and treatment of cancer, infections, autoimmune diseases, metabolic genetic diseases, and many other diseases, largely due to their advantages of high specificity, low toxicity, and defined biological functions. They are now the fastest-growing segment of the global pharma market.

However, due to the nature of biological macromolecules, proteins also have their own problems. Because of their large molecular weight, complex composition and structure, many proteins have limited solubility and thermal and proteolytic stability. They can be denatured during storage or are prone to aggregation and chemical modifications, such as oxidation and deamidation. The existence of these problems can result in decreased efficacy of therapeutic proteins and increased immunogenic side effects. Glycoengineering is a method of improving the properties of proteins by changing their glycosylation.

Fig 1. Overview of mammalian N-glycosylation.Fig.1 Overview of mammalian N-glycosylation. (Dammen-Brower, et al.,2022)

Glycoengineered Protein-based Glycomedicine Development Sevices

CD BioGlyco has developed a highly specialized carbohydrate-based glycomedicine development platform and various systematic solutions for glycoengineered protein-based glycomedicine development. Our services include but are not limited to:

  • Mammalian cells-based glycoengineering.
    (a) To modify the structure of glycans on proteins through gene knockout technologies. (b) Changing the number of glycosylation sites. (c) Metabolic glycoengineering. For example, increasing the number of N-linked carbohydrates by recombinant gene technology with Chinese hamster ovary cells to increase the half-life of derivatives in blood. By attaching carbohydrates to particular positions of compounds to achieve new functional characteristics (e. g., prolonged half-life in blood, improved solubility in water, etc.).
  • Non-mammalian cells-based glycoengineering.
    (a) Production of more homogeneous glycoproteins by plant cells than those synthesized by mammalian cells. (b) Rapid production of glycoproteins and high tolerance for manipulation of the N-glycan biosynthetic pathway. (c) Applied for the glycoengineering of industrial enzymes.
  • Chemistry-based protein glycoengineering.
    Simplify the complexity of glycoprotein samples by using techniques for protein glycosylation pathway engineering as well as techniques based on the use of biochemistry and organic chemistry.
  • Biochemistry-based glycoengineering.
    Protein glycoengineering based on biochemistry methods is mainly accomplished through the use of biochemical reactions catalyzed by a variety of glycosidases and glycosyltransferases. For example, the development of a cell-free glycoprotein synthesis technology.
  • Organic chemistry-based glycoengineering.
    Engineering O-linked protein glycosylation can be achieved by organic synthesis. The current strategy for glycoprotein synthesis relies on native chemical ligation/metal-free desulfurization to connect synthetic peptides and glycopeptide fragments. After that, the resulting long glycopeptide chains can be folded in vitro to form biologically active glycoproteins.
  • Combination strategy. Organic and/or enzymatic synthesis is used to deeply understand the structure-property relationships of representative model glycoproteins that have relatively small sizes and simple structures. Theoretical predictions derived from the high-level understanding of protein glycosylation can then be used to guide protein glycoengineering efforts.

Advantages of Us

  • A comprehensive and advanced platform.
  • Cutting-edge technology and professional research team.
  • Extensive experience in the field of glycomedicine development.
  • Efficient, fast, and practical service.

CD BioGlyco aspires to become the trusted solution provider of your first choice. Our advanced technologies and highly experienced staffs are committed to advancing your program and reducing the overall development timeline. Our professional research teams provide customers with high-quality glycoengineered protein-based glycomedicine development according to their needs. For further details, please don't hesitate to contact us.

Reference:

  1. Dammen-Brower, K.; et al. Strategies for glycoengineering therapeutic proteins. Frontiers in Chemistry. 2022, 10.
This service is for Research Use Only, not intended for any clinical use.

Christmas

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.